Cell for delivering gene or therapeutic drug, and use thereof
By designing a direct contact delivery system for virus-like capsid protein mutant and donor delivery cells, the shortcomings of existing gene therapy vectors in terms of delivery efficiency and safety are solved, and efficient delivery of complex tissues and organs and neural cells are achieved. Effective treatment reduces side effects and preparation costs.
Patent Information
- Application Number
- PCT/CN2024/092906
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-19
- Filing Date
- 2024-05-13
- Publication Date
- 2024-11-28
AI Technical Summary
Existing gene therapy vectors such as adeno-associated viral vectors and nanoparticle vectors have insufficient delivery efficiency and safety, making it difficult to achieve efficient delivery of certain complex tissues and organs, and are inefficient in infection with nerve cells, which can easily cause system immunity. Reactions, resulting in side effects and reduced delivery efficiency.
Designing to construct defective virus-like particles using viroid particle capsid protein mutants, and deliver genes or therapeutic drugs through direct contact between donor delivery cells and recipient target cells, avoiding the purification and secretion dependence of virus particles, and improving the Delivery system specificity and efficiency.
It significantly improves the delivery efficiency and specificity of gene or gene therapy drugs, simplifies the vector preparation process, reduces production costs, and is able to cross the internal barrier to reach difficult-to-reach locations, reducing side effects.
Smart Images

Figure CN2024092906_28112024_PF_FP_ABST
Abstract
Description
A cell for delivering genes or therapeutic drugs and its use Technical Field
[0001] The present invention relates to the fields of cell engineering and gene therapy, and in particular to a cell carrier for delivering genes or therapeutic drugs. Background Art
[0002] Gene therapy involves delivering exogenous, functional genes or gene-editing drugs via a vector into target cells within the human body, correcting defective genes to treat the disease. If chemotherapy is a temporary solution, gene therapy is a permanent solution. As gene therapy gradually emerges in clinical applications, it has become one of the fastest-growing areas of biomedicine in recent years. Most gene therapies involve obtaining modified functional cells locally or in vitro, which are then transplanted into the patient. Drug delivery vectors are a key technology in gene therapy, and commonly used vectors include viral and non-viral vectors.
[0003] In order to overcome the various shortcomings of gene therapy delivery vectors currently used on the market, such as adeno-associated virus vectors (AAV) and nanoparticle vectors (LNP), new virus-like particle vectors (VLP) have been developed (Zhang Feng, David Liu of MIT, Jennifer Doudna of UC Berkeley, etc.). The so-called virus-like particle vectors (VLP) are composed of one or more structural proteins of a virus that are recombinantly expressed in an expression system and self-assembled to form virus-like protein particles that do not contain viral genetic material, cannot replicate, and do not have full infection ability. Cell-free virus-like particle vectors can, to a certain extent, achieve the purpose of instantaneous and efficient delivery of genes or gene therapy drugs, thereby ensuring the effectiveness of gene therapy (editing) while reducing its off-target effects and alleviating its side effects. Virus-like particles are usually expressed, assembled, and purified in an expression system (such as donor delivery cells). These virus-like particles are then delivered into the body by systemic injection (intravenous injection) or local injection, or directly in vitro to infect target cells, and deliver genes or gene therapy drugs into the target cells to complete gene editing or replacement. The target cells that have completed gene editing or correction are then re-infused, thereby achieving fundamental treatment of the disease.
[0004] Although VLPs derived from many important viruses have been developed and applied in clinical treatment, they still have many shortcomings: 1) high doses of VLPs are required to achieve gene or gene therapy drug delivery, which requires a large number of donor delivery cells to complete VLP production. Subsequently, a tedious VLP purification process is still required to obtain the purified product, and its production cost is very high; 2) VLPs have difficulty passing various tissue barriers in the body, making it difficult to achieve efficient delivery in certain complex tissues and organs; 3) VLPs are not efficient in infecting certain cells, such as neurons, and cannot effectively deliver genes or gene therapy drugs in diseases related to these receptor target cells; 4) VLPs have viral shells and envelope proteins, which are more likely to cause systemic immune responses (such as complement reactions), causing drug-related side effects and reducing their delivery efficiency. Therefore, new gene therapy methods still need to be developed to improve the targeted therapeutic effect of genes or gene therapy drugs.
[0005] Current cell-based gene therapy technologies and tools are often prone to unwanted and dangerous side effects. In U.S. Patent No. US11248213B2, cytoplasmic bodies, compositions comprising cytoplasmic bodies, methods of using cytoplasms, and methods of treating subjects are provided, such as providing benefits to healthy or unhealthy subjects, or treating or diagnosing diseases or conditions in subjects. In U.S. Patent No. US20230015661A1, a method for treating diseases using bioengineered enucleated cells is provided. The patent also provides a composition comprising enucleated cells, wherein the enucleated cells are loaded with clinically relevant biomolecules and mentions the use of enucleated cells to deliver therapeutic viruses such as oncolytic viruses. In Chinese Patent No. CN113226336A, immune cells are used as carriers for virus packaging and transport to complete the delivery of intercellular genes, thereby changing their original properties or generating new properties in the receptor target cells. However, the invention does not involve the delivery of virus-like particles.
[0006] Summary of the Invention
[0007] There are two main ways for viruses and virus-like particles to be transmitted between cells: through direct cell-to-cell interaction and through the release of free virus-like particles. This invention, for the first time, utilizes mutant virus-like particle capsid proteins to construct virus-like particles with budding or release defects. This significantly reduces budding and release of virus-like particles in donor delivery cells, forcing virus-like particles to rely primarily on direct cell-to-cell contact for delivery. This uniquely designed delivery system offers greater specificity and improved delivery efficiency.
[0008] The present invention involves modifying cells to create donor delivery cells for virus-like particles. These donor delivery cells, through direct contact with target cells in vivo or in vitro, deliver virus-like particles containing genes or gene therapy drugs directly to target cells, eliminating the need for purification of the virus particles and relying on their secretory capacity. Ultimately, these cells alter or treat specific genes in the target cells.
[0009] In a first aspect, the present invention provides a gene or gene therapy drug delivery system, wherein the delivery system comprises a donor delivery cell containing virus-like particles.
[0010] Furthermore, the delivery system delivers virus-like particles directly into recipient target cells via donor delivery cells.
[0011] Furthermore, the delivery system relies on direct cell-cell interaction between donor delivery cells and recipient target cells to deliver virus-like particles.
[0012] Furthermore, the delivery system can deliver virus-like particles with infectious ability, and can also deliver virus-like particles without infectious ability.
[0013] Furthermore, the delivery system can deliver virus-like particles with or without maturation capabilities.
[0014] Furthermore, the delivery system can deliver virus-like particles with secretion ability, and can also deliver virus-like particles without secretion ability.
[0015] Furthermore, the delivery system can deliver virus-like particles with fusion ability, and can also deliver virus-like particles without fusion ability.
[0016] Furthermore, the delivery is independent of the secretion capacity of virus-like particles.
[0017] Furthermore, the donor delivery cells are cells carrying VLP virus-like particles carrying genes or gene therapy drugs.
[0018] Furthermore, the virus-like particles contain genes or gene therapy drugs.
[0019] Furthermore, the gene or gene therapy drug includes a DNA recombinase system, a CRISPR-Cas 9 system, a ZFN (Zinc Finger Nuclease) system, a transposon system, a TALEN system, a Prime-editing system and / or a gene epigenetic modification system, etc.
[0020] Furthermore, the donor delivered cells can be human cells or cells from other mammals.
[0021] Furthermore, the donor delivery cells can be enucleated cells or nucleated cells.
[0022] Furthermore, the diameter of the cells delivered by the donor is ≥5 microns.
[0023] Furthermore, the donor delivered cells can be suspension cells, adherent cells or partially adherent cells.
[0024] Furthermore, the donor delivered cells include but are not limited to epithelial cells, bone cells, cardiomyocytes, muscle cells, neurons, glial cells, immune cells, blood cells, bone marrow cells, stem cells, tumor cells, somatic cells with or without the ability to divide, etc.
[0025] Furthermore, the donor delivered cells are preferably immune cells that can form immune synapses.
[0026] Furthermore, the donor delivered cells are preferably T cells, such as edited and modified CAR-T cells.
[0027] Furthermore, the donor delivery cells containing virus-like particles refer to donor delivery cells that have been subjected to cell engineering so that VLPs enter the donor delivery cells. The cell engineering transformation includes but is not limited to the transformation of cell membrane receptors, mitochondria, cytoskeleton, movement and migration capabilities, and / or the transformation of the ability to interact with other cells.
[0028] Furthermore, the cell engineering transformation methods of the donor delivery cells include, but are not limited to, transformation using plasmids, transformation using RNA, transformation using lentivirus, transformation using other viruses, and / or transformation using a transposon system.
[0029] Furthermore, the virus-like particles do not include the genetic material of the virus, that is, do not include the DNA or RNA genome of the virus itself.
[0030] Furthermore, the virus-like particles do not have the ability to replicate themselves.
[0031] Furthermore, the virus-like particle includes part or all of the virus's capsid protein, envelope protein and / or other structural proteins.
[0032] Furthermore, the virus-like particles include one or more of the virus's capsid protein, envelope protein and other structural proteins.
[0033] Furthermore, to limit the budding and release of virus-like particles in donor delivery cells, the preferred capsid protein is a capsid protein with budding or release function defects. The ability of virus-like particles coated with mutant capsid proteins to bud and be released from donor delivery cells is 0%-90% of that of wild-type.
[0034] Furthermore, the capsid protein, envelope protein and other structural proteins of the virus-like particles may be derived from the same virus or different viruses.
[0035] Furthermore, the capsid protein, envelope protein and other structural proteins of the virus-like particles may be derived from RNA viruses or DNA viruses or a combination thereof.
[0036] Furthermore, the capsid protein, envelope protein and other structural proteins of the virus-like particles can be derived from one or more of retrovirus, adeno-associated virus, adenovirus, lentivires, coronavirus, rabies virus and herpes virus.
[0037] Furthermore, the capsid protein, envelope protein and other structural proteins of the virus-like particles are preferably derived from retroviruses;
[0038] Furthermore, among retroviruses, murine leukemia virus (MLV) is preferred.
[0039] Furthermore, the capsid protein is preferably the capsid protein MLV GAG and its mutants.
[0040] The mutant comprises one or more of the following peptide segments:
[0041] GAG WT (aa128-225)
[0042] GAG S2D(aa128-225)
[0043] GAG△P12(aa128-143)
[0044] GAG WT (aa429-511)
[0045] GAG S3R(aa429-511)
[0046] GAG WT (aa453-538)
[0047] GAG△NC(16-23)(aa453-530)
[0048] GAG△NC60(aa453-478)
[0049] Furthermore, the capsid protein, envelope protein and other structural proteins of the virus-like particles can also be derived from endogenous virus-like proteins that are similar to viral capsid proteins and are not of viral origin.
[0050] In a specific embodiment, the virus-like particle capsid protein is preferably mammalian retrovirus-like protein PEG10 and its mutants.
[0051] Furthermore, the virus-like particles may include genetic material from exogenous and / or non-homologous viral sources, including DNA or RNA.
[0052] Furthermore, the purpose of the gene or gene therapy drug delivery system is to perform gene therapy, which includes introducing exogenous normally expressed nucleic acids, proteins or their complexes to correct, compensate for defects, or silence specific genes in the recipient target cells to achieve the purpose of benefiting the subject.
[0053] Furthermore, the gene or gene therapy drug refers to a nucleic acid and / or its complex that can edit, insert or replace a gene to correct, compensate for defects or silence a specific gene to normally express proteins, enzymes, polypeptides.
[0054] Furthermore, the nucleic acid and its complex refer to normally expressed exogenous or endogenous single-stranded DNA and / or RNA or modified exogenous or endogenous single-stranded DNA and / or RNA.
[0055] Furthermore, the exogenous RNA may include circular RNA.
[0056] Furthermore, nucleic acids and their complexes also include modified DNA or RNA.
[0057] Furthermore, the modification includes modification or replacement of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), 5-carboxylcytosine (5caC), N6-methyladenine, N4-methylcytosine (4mC) and / or pseudouracil (Pseudouridine).
[0058] Furthermore, the recipient target cells are homologous or heterologous cells of the donor delivered cells, including epithelial cells, bone cells, cardiomyocytes, muscle cells, neurons, glial cells, immune cells, blood cells, bone marrow cells, stem cells, tumor cells, somatic cells with or without the ability to divide.
[0059] Furthermore, the direct contact between the donor delivery cells and the recipient target cells can occur in vivo or in vitro.
[0060] Furthermore, the direct contact between cells may occur in the human body or in an animal body.
[0061] Furthermore, the direct cell-cell contact can occur in the lung, liver, brain, heart, kidney, bone marrow, blood, or other tissues.
[0062] Furthermore, the direct cell-to-cell contact includes in vitro cell co-culture, which refers to a physical connection between the donor delivery cell and the recipient target cell, including tight junctions, anchoring connections, communication connections, etc., and also includes connections formed by filopodia, connections formed by tunneling nanotubes, connections formed by receptor-ligand interactions, immunological synapse connections, virological synapse connections, neurological synapse connections, etc. Among them, immunological synapse connections are preferred.
[0063] In a second aspect, the present invention provides a delivery method that can be used to deliver genes or gene therapy drugs to recipient target cells, the method comprising directly contacting a donor delivery cell containing the gene or gene therapy drug with the recipient target cell, and achieving direct transfer of the gene or gene therapy drug from the donor delivery cell to the recipient target cell.
[0064] Furthermore, the delivery method is direct contact between the donor delivery cells and the recipient target cells.
[0065] Furthermore, the direct contact between the donor delivery cells and the recipient target cells is preferably performed in vitro.
[0066] Furthermore, the direct contact between cells may occur in the human body or in an animal body.
[0067] Furthermore, the direct cell-cell contact can occur in the lung, liver, brain, heart, kidney, bone marrow, blood, or other tissues.
[0068] Furthermore, the direct contact between cells includes in vitro cell co-culture, wherein the distance between cells is 0-1 mm.
[0069] In a third aspect, the present invention provides a use of the gene or gene therapy drug delivery system described in the first aspect of the present invention in the preparation of drugs for improving physical condition or treating genetic diseases.
[0070] Furthermore, the improvement of physical condition includes improvement of weight, improvement of aging, and improvement of physical fitness.
[0071] Furthermore, the genetic diseases include hereditary diseases, further including but not limited to thalassemia, sickle cell anemia, hereditary retinal degeneration, specific lymphoma, familial hypercholesterolemia, cystic fibrosis, spinal muscular atrophy (SMA), etc.
[0072] Furthermore, the drug is preferably an injectable preparation, which is administered to a subject in need thereof by intravenous injection (intravenous injection), intramuscular injection (muscular injection), subcutaneous injection (subcutaneous injection), intratumoral injection, intracranial injection, etc.
[0073] Beneficial effects of the present invention:
[0074] The delivery method of the present invention can greatly improve the delivery efficiency of genes or gene therapy drugs; at the same time, it can greatly improve the specificity of gene or gene therapy drug delivery; at the same time, it can greatly simplify the preparation process and preparation cost of gene or gene therapy drug delivery vectors; the delivery system of the present invention can penetrate various barriers in the body, such as the endothelial barrier and the blood-brain barrier, by utilizing the active homing ability of the donor delivery cells endogenous or acquired after modification, and deliver VLPs to locations difficult to reach by ordinary methods. BRIEF DESCRIPTION OF THE DRAWINGS
[0075] Figure 1: Schematic design. It consists of three components: 1. Donor delivery cells; 2. VLPs; 3. Delivered gene therapy. The gene therapy is encapsulated within the VLPs, which attach to the inner membrane of the donor delivery cells. Direct contact between the donor delivery cells and the recipient target cells allows the VLPs to be delivered to the recipient target cells, where they undergo gene editing.
[0076] Figure 2: Bar graph comparing the results of delivering VLPs containing CRE recombinase by direct contact between donor delivery cells and recipient target cells in an in vitro co-culture system with existing VLP delivery methods.
[0077] FIG3 is a bar graph showing the effect of adjusting the concentration of the envelope protein pMD 2.G plasmid on the direct cell delivery efficiency.
[0078] Figure 4: Bar graph showing the difference in direct delivery efficiency of the envelope protein Friend MLVEnvYFP plasmid to 293 cells without FMLVENV membrane receptors and XC cells with FMLVENV membrane receptors.
[0079] Figure 5: Bar graph showing the differences in budding rates of VLPs packaged with wild-type and mutant GAG plasmids alone.
[0080] Figure 6: GAG mutants increase the efficiency of direct delivery of VLPs to recipient target cells via cell vectors, as reflected by the proportion of gene recombination events that occur in recipient target cells after receiving VLPs carrying the CRE gene recombinase.
[0081] Figure 7: Donor delivery cells (T cells) were edited and modified by genetic engineering methods to overexpress CD19 CAR on T cells, and the proportion of CD19 CAR T cells activated.
[0082] Figure 8: CD19 CAR-T cells can deliver VLPs to receptor target cells expressing the corresponding antigen via direct delivery, with significantly higher delivery efficiency than indirect delivery (delivery via VLPs released after budding).
[0083] Figure 9: CD19 CAR-T cells directly contact target cells expressing the corresponding antigen and deliver VLPs to the target cells. Green fluorescence marks the target cells, and red fluorescence marks the delivered VLPs.
[0084] Figure 10: A. CD19 CAR-T cells can specifically recognize target cells expressing CD19 and selectively deliver VLPs through direct cell-cell contact. B. VLPs themselves cannot specifically recognize target cells expressing or not expressing CD19.
[0085] Figure 11: At different ratios of donor delivery cells and recipient target cells, the edited donor delivery cells (CD19 CAR-T) cells achieved the best delivery efficiency to CD19-expressing recipient target cells.
[0086] Figure 12: Delivery specificity was further improved by delivering VLPs assembled from a budding mutant of the capsid protein GAG to CAR-T cells. A, Ratio of gene recombination of VLPs delivered by CAR-T cells to CD19 receptor target cells compared to control target cells; B, Ratio of gene recombination of VLPs delivered by CAR-T cells to CD19 receptor target cells compared to control T cells. DETAILED DESCRIPTION
[0087] Cre recombinase belongs to the λInt enzyme supergene family. The coding region of the Cre recombinase gene is 1029 base pairs (EMBL database accession number X03453), encoding a 38 kDa monomeric protein composed of 343 amino acids. It not only possesses catalytic activity but also, similar to restriction enzymes, recognizes specific DNA sequences, namely LoxP sites, enabling deletion or recombination of the gene sequence between the LoxP sites. Cre recombinase has a 70% recombination efficiency and operates without the aid of any cofactors on a variety of DNA substrate structures, including linear, circular, and even supercoiled DNA.
[0088] It is a site-specific recombinase that can mediate specific recombination between two LoxP sites (sequences), causing the gene sequence between the LoxP sites to be deleted or recombined. Cre recombinase-mediated recombination between two LoxP sites is a dynamic and reversible process that can be divided into three situations: (1) If the two LoxP sites are located on the same DNA chain and in the same direction, Cre recombinase can effectively remove the sequence between the two LoxP sites; (2) If the two LoxP sites are located on the same DNA chain but in opposite directions, Cre recombinase can cause sequence inversion between the two LoxP sites; (3) If the two LoxP sites are located on two different DNA chains or chromosomes, Cre enzyme can mediate the exchange of the two DNA chains or chromosome translocation. In addition, Cre can not only recognize the two 13bp inverted repeat sequences and 8bp spacer region of LoxP, but also can still recognize and undergo recombination when a 13bp inverted repeat sequence or 8bp spacer region changes. Taking advantage of this feature, the LoxP site sequence can be modified as needed when constructing the vector for specific gene mutation or repair, expanding the application range of the system.
[0089] Virus-like particles (VLPs): The virus-like particles used in the present invention refer to the expression of retroviruses such as MLV, or other viruses, or viral residues such as PEG10 capsid proteins, membrane-associated proteins, envelope proteins, and the gene or gene therapy drug complex (protein, RNA, DNA, or a complex thereof) to be delivered in adherent cells or suspended cells through 2-3 plasmids or lentiviral vectors (or other similar vectors). These modified donor delivery cells are directly co-cultured with target receptor target cells in vitro to achieve efficient delivery of VLPs containing genes or gene therapy drugs; or through systemic injection (such as intravenous injection) or local injection (such as ocular injection), the donor delivery cells are targeted to home to the target tissue and directly contact the target receptor target cells to achieve efficient delivery of VLPs containing genes or gene therapy drugs in vivo.
[0090] The term "direct cell-to-cell contact" as used herein refers to the physical connection between the donor delivery cell and the recipient target cell formed through various cell connections. These direct contacts can be mediated by ligand-receptor interactions, antibody-antigen interactions, and other protein-protein, protein-sugar, and protein-lipid interactions, including tight junctions, anchoring junctions, and communication junctions. They also include connections formed by filopodia, connections formed by tunneling nanotubes, connections formed by receptor-ligand interactions, immunological synapse connections, virological synapse connections, and neurological synapse connections.
[0091] Example 1 Construction of a receptor target cell (LSL-mCherry cell) stably expressing the GFP-Loxp-Stop-Loxp-mCherry gene recombination reporter system
[0092] To test the delivery efficacy of the gene recombinase acting on the genomic DNA of target cells, the GFP-Loxp-Stop-Loxp-mCherry sequence was inserted into the genome of target cells (e.g., primary human embryonic kidney cells (HEK293), rat Wistar sarcoma cells (XC), and immortalized human T lymphocyte cell lines (Jurkat T)) using the Piggybac transposon system. Cells that highly expressed green fluorescent protein (GFP) but did not express red fluorescent protein (mCherry), i.e., stably expressing GFP-Loxp-Stop-Loxp-mCherry, were then screened using a flow cytometer.
[0093] 1.1 Preparation of HEK293 cells
[0094] 1) Resuscitate 293 cells and culture at 37°C in a 5% CO2 environment to allow the cells to enter the logarithmic growth phase;
[0095] 2) Digest the 293 cells with trypsin and add DMEM complete medium and about 1×10 6 The cells were plated so that the density could reach 70-80% the next day.
[0096] 1.2 Transfection of 293 cells
[0097] 1) Preheat DMEM complete medium and Opti-MEM to 37°C.
[0098] 2) Replace the 293 cell culture medium prepared the day before with fresh DMEM complete medium;
[0099] 3) Mix opti-MEM with plasmids pBase and pGFP-Puro-LSL-mCherry, then add lipofactamine 3000 and P3000 solution, mix well, and let stand at room temperature for 5 minutes;
[0100] 4) Carefully add the mixed solution dropwise to the 293 cell culture medium, gently shake to mix, and incubate at 37°C.
[0101] 5) 4-6 hours after transfection, replace the 293 cell culture medium with fresh DMEM complete medium;
[0102] 6) Perform appropriate passage and cell expansion according to the growth status of the transfected 293 cells.
[0103] 1.3 Sorting LSL-mCherry 293 cells
[0104] 1) After the transfection, 293 cells were expanded to a certain number (about 20×10 6 ), and a portion of 293 cells expressing green fluorescence (GFP) can be observed under a fluorescence microscope, and cell sorting can be performed;
[0105] 2) Digest the transfected 293 cells with TrypLE and collect the cells by centrifugation at 300 g for 5 minutes;
[0106] 3) Wash the cells once with 10 mL of FACS buffer (D-PBS containing 0.5-2% serum) and collect the cells by centrifugation at 300 g for 5 min.
[0107] 4) Resuspend the cells in an appropriate amount of FACS buffer to a cell density of approximately (2-5) × 10 6 / mL, transferred to a 5mL flow tube;
[0108] 5) Flow cytometry is used to sort cells that highly express green fluorescence (GFP) but do not express red fluorescence (mCherry), which are the receptor target cells (LSL-mCherry 293 cells);
[0109] 6) The receptor target cells (LSL-mCherry 293 cells) were cultured and frozen for subsequent experiments.
[0110] A similar method was used to construct other receptor target cells: LSL-mCherry XC cells, LSL-mCherry Jurkat T cells and other receptor target cells containing gene recombination reporter systems.
[0111] Example 2 Construction of donor delivery cells containing virus-like particles
[0112] The MLV gag-CRE fusion protein plasmid capable of expressing the CRE gene recombinase is transferred into virus-like particles (VLPs), and the aforementioned VLPs are then transfected into donor delivery cells (eg, 293T, MSC, JurkatT, etc.).
[0113] If VLPs can deliver the CRE gene recombinase to target cells, LoxP-mediated DNA recombination can be completed, causing the target cells to express both GFP and mCherry simultaneously instead of solely GFP. By measuring the proportion of GFP / mCherry double-positive cells among all GFP-labeled target cells, the proportion of cells that have successfully undergone genetic recombination, that is, the proportion that has successfully received the CRE gene recombinase, can be determined, reflecting the VLP delivery efficiency.
[0114] The capsid protein of the VLP of this example is MLVgag-pro-pol, and the envelope glycoprotein is pMD 2.G (WT VSV-G).
[0115] 2.1 Preparation of 293T cells (donor delivery cells)
[0116] 1) Resuscitate 293T cells and culture at 37°C in a 5% CO2 environment to allow the cells to enter the logarithmic growth phase;
[0117] 2) Digest the 293T cells with trypsin and add DMEM complete medium and about 7×10 6 The cells were plated so that the density could reach 90-95% the next day.
[0118] 2.2 Transfection of 293T cells (Day 2)
[0119] 1) Preheat DMEM complete medium and Opti-MEM to 37°C.
[0120] 2) Replace the 293T cell culture medium prepared in 2.1 with fresh DMEM complete medium;
[0121] 3) Mix opti-MEM with plasmids pBS-CMV-gagpol (MLV gag and pol), pRP[Exp]-CMV+intron>{MMLVgag-3XNES-NLSCRE}(MMLVgag-3NES-Cre), and pMD 2.G (WT VSV-G), then add lipofactamine 3000 and P3000 solution, mix well, and let stand at room temperature for 20 minutes; (Please refer to Thermo Fisher's Lipofectamine TM 3000 Reagent Protocol)
[0122] 4) Carefully add the mixed solution dropwise to the 293T cell culture medium, gently shake to mix, and incubate at 37°C.
[0123] 5) 4-6 hours after transfection, 293T cells capable of producing VLPs containing Cre recombinase were obtained and designated 293T (VLP-CRE) cells. The culture medium was replaced with fresh DMEM complete medium.
[0124] 6) After culturing for 24-48 hours, the 293T (VLP-CRE) cells were used as one of the donor delivery cells of the present invention and were used for subsequent experiments.
[0125] Example 3 Comparison of the efficiency of different delivery methods
[0126] This experiment was designed with three groups. The first group (direct delivery group): donor delivery cells and recipient target cells (LSL-mCherry cells) were co-cultured in direct contact; the second group (indirect delivery non-concentration group): donor delivery cells and recipient target cells were co-cultured in non-direct contact (physically isolated, but the culture system was connected); the third group (indirect delivery concentrated VLP group) collected and purified the free VLPs produced by the donor delivery cells and co-cultured them with the recipient target cells.
[0127] 3.1 Preparation of target cells (LSL-mCherry 293 cells)
[0128] The preparation process was the same as in Example 1. LSL-mCherry 293 cells in the logarithmic growth phase were digested and 0.1×10 6 The cells were seeded in 24-well plates for subsequent experiments.
[0129] 3.2 Direct delivery group:
[0130] Recipient target cells (LSL-mCherry 293 cells) were co-cultured in direct contact with donor delivery cells (293T (VLP-CRE) cells) for 48 h;
[0131] 1) 24 hours after 293T cell transfection, the 293T (VLP-CRE) cells were digested and centrifuged at 500 g for 5 minutes to collect the cells;
[0132] 2) Add fresh DMEM complete medium to resuspend the cells and count them;
[0133] 3) Replace the medium in the 24-well plate containing LSL-mCherry293 cells and add an appropriate amount of fresh DMEM complete medium;
[0134] 4) Dilute 293T (VLP-CRE) cells to an appropriate concentration of 0.1×10 per well. 6 The amount of cells added to the corresponding position of the 24-well plate allows LSL-mCherry 293 cells and 293T (VLP-CRE) cells to be in sufficient direct contact for co-culture.
[0135] 3.3 Indirect transmission non-enrichment group:
[0136] Recipient target cells (LSL-mCherry 293 cells) were co-cultured with donor delivery cells (293T (VLP-CRE) cells) in indirect contact for 48 hours (VLPs were delivered by secretion)
[0137] 1) Collecting recipient target cells and donor delivery cells, and processing them in the same manner as the direct delivery group step;
[0138] 2) Place an 8 μm Transwell chamber (Corning, #3422) on the wells of the indirect transfer non-concentration group;
[0139] 3) Dilute the donor delivered cells to an appropriate concentration of 0.1×10 per well 6 The amount of cells is carefully added to the transwell chamber of a 24-well plate so that the recipient target cells and the transfected donor delivery cells can be indirectly co-cultured through the transwell chamber. The remaining wells can serve as a control group.
[0140] 3.4 Indirect delivery of concentrated VLP groups
[0141] Collect and purify the free VLPs produced by the donor delivery cells and co-culture them with the recipient target cells. For the method of purifying VLPs, please refer to the prior art (Cell. 2022; 185(2): 250-265.e16.), and the detailed steps are as follows:
[0142] 1) Collect VLPs containing CRE enzyme
[0143] Step 1: 24 h after 293T cell transfection, collect the cell culture medium (containing VLPs), centrifuge at 500g for 5 min, filter the supernatant through a 0.45 μm filter (to remove cells), and collect it in a 50 mL centrifuge tube;
[0144] Step 2: Add 1 / 4 volume of PEG-it virus precipitation solution (SBI, LV810A-1) based on the volume of the supernatant, mix well, and incubate at 4°C overnight (at least 12 hours, up to 4-5 days).
[0145] Step 3: Count the 293T (VLP-CRE) cells producing VLP-CRE for quantitative comparison;
[0146] Step 4: The next day, centrifuge the mixture of cell culture medium containing VLPs and PEG-it virus precipitation solution at 4°C, 1500g for 30 minutes, remove the supernatant, and resuspend the precipitate (containing VLPs) with the corresponding volume of PBS according to the concentration multiple required by the experiment.
[0147] 2) Recipient target cells were co-cultured with concentrated VLPs for 48 hours.
[0148] 3.5 Experimental Results
[0149] As shown in Figure 2, the mCherry / GFP fluorescence of three groups of receptor target cells was quantitatively analyzed by flow cytometry (Beckman Coulter); the control group was 0.1×10 6 LSL-mCherry 293 cells were cultured alone; the direct delivery group was 0.1×10 6 LSL-mCherry 293 cells + 0.1 × 10 6 293T (VLP-CRE) cells were co-cultured in direct contact; the indirect transfer non-concentrated group was 0.1×10 6 LSL-mCherry 293 cells + 0.1 × 10 6 293T (VLP-CRE) cells were co-cultured in transwell chambers but not in direct contact; the indirect delivery concentrated VLP groups were VLPs concentrated 50 times, 10 times, and 2 times with the same volume and 0.1×10 6 Culture medium for LSL-mCherry 293 cells.
[0150] The results are shown in Figure 2. The vertical axis represents the proportion of gene recombination events (i.e., the proportion of cells expressing mCherry to cells expressing GFP, Figures 2 to 4, 6, 8, 10 to 12). Direct delivery group (second column, from left to right): donor cells expressing the designed VLP were delivered (0.1×10 6cells) and receptor target cells (0.1×10 6 In the same batch, the same number of donor cells and recipient target cells in the indirect delivery non-concentration group (column 3) were separated by Transwell, so that they were still in the same culture system (i.e., the culture medium was connected), but they could not directly contact each other (about 1 mm apart). Therefore, the occurrence of genetic recombination events could not be detected. In the indirect delivery concentrated VLP group (columns 4-6), VLPs were first purified and concentrated according to existing technology, and then concentrated 50 times, 10 times, and 2 times respectively, and then added to 0.1×10 6 Among the receptor target cells, only the receptor target cells added with 50-fold and 10-fold concentrated VLPs were able to obtain obvious gene recombination events (the fourth and fifth columns); while the gene recombination events of the receptor target cells added with 2-fold concentrated VLPs were significantly lower than those in the direct cell delivery group (the sixth column).
[0151] Therefore, this experiment proves that the existing technology of directly delivering gene therapy (recombinant) drugs to receptor target cells through purified VLPs requires a very high VLP concentration; while delivering VLPs through direct cell-cell interaction can greatly reduce this requirement and significantly improve delivery efficiency.
[0152] Example 4 Adjusting the Concentration of Envelope Protein pMD 2.G (WT VSV-G) Plasmid to Improve Direct Cell Co-culture Delivery Efficiency
[0153] 4.1 Refer to the experimental steps of transfecting 293T (VLP-CRE) cells (donor delivery cells) in Example 2, and finally add DMEM complete medium and about 1×10 6 The cells were cultured until the cell density reached 90-95% the next day. The plasmids transfected the next day were pBS-CMV-gagpol, MMLVgag-3NES-Cre, and different concentrations of pMD 2.G (WT VSV-G). The concentrations of pMD 2.G (WT VSV-G) are as follows:
[0154] 4.2 Prepare receptor target cells (LSL-mCherry 293 cells) according to Example 3, and directly co-culture LSL-mCherry 293 cells with 293T (VLP-CRE) cells transfected with different concentrations of pMD 2.G (WTVSV-G) plasmid according to the direct transfer group steps.
[0155] 4.3 Experimental Results
[0156] Flow cytometry was used to quantitatively analyze the mCherry / GFP fluorescence of LSL-mCherry 293 cells (day 5). The results were as follows: the control group was 0.1×10 6 LSL-mCherry 293 cells were cultured alone; 0.2ug group was 0.1×10 6 LSL-mCherry 293 cells + 0.1 × 10 6 293T (VLP-CRE) cells were co-cultured. The concentration of pMD 2.G (WT VSV-G) plasmid was 0.2 μg when transfecting 293T cells; 0.4 μg group: 0.1×10 6 LSL-mCherry 293 cells + 0.1 × 10 6 293T (VLP-CRE) cells were co-cultured. The concentration of pMD 2.G (WT VSV-G) plasmid was 0.4 μg when transfecting 293T cells; 0.8 μg group: 0.1×10 6 LSL-mCherry 293 cells + 0.1 × 10 6 293T (VLP-CRE) cells were co-cultured. The concentration of pMD 2.G (WT VSV-G) plasmid was 0.8 μg when transfecting 293T cells; 0.1×10 6 LSL-mCherry 293 cells + 0.1 × 10 6 293T (VLP-CRE) cells were co-cultured, and the concentration of pMD 2.G (WT VSV-G) plasmid was 2 μg when transfecting 293T cells.
[0157] By transfecting different concentrations of the envelope protein VSV-G plasmid, different gene recombination efficiencies (VLP delivery efficiency) were achieved and further optimized. The results showed that 0.8 μg of the plasmid PMD 2.G (WT VSV-G) achieved the optimal VLP delivery and gene recombination efficiency in target cells (see Figure 3).
[0158] Example 5: Differences in the delivery efficiency of the envelope protein Friend MLV Env YFP plasmid to 293 cells without FMLV ENV membrane receptors and XC cells with FMLV ENV membrane receptors
[0159] 5.1 Refer to the experimental steps of transfecting 293T (VLP-CRE) cells (donor delivery cells) in Example 2, and finally add DMEM complete medium and about 1×10 6The cells were cultured to a density of 90-95% the next day. The plasmids transfected the next day were pBS-CMV-gagpol, MMLVgag-3NES-Cre, and 0.8 μg Friend MLV Env YFP.
[0160] 5.2 Prepare receptor target cells (LSL-mCherry 293 cells) according to Example 3, and directly co-culture LSL-mCherry 293 cells with 293T (VLP-CRE) cells according to the direct transfer group steps.
[0161] 5.3 Experimental Results
[0162] The mCherry / GFP fluorescence of LSL-mCherry 293 cells and LSL-mCherry XC cells was quantitatively analyzed by flow cytometry (day 5). The results are shown in Figure 4. The mCherry / GFP fluorescence of the 293 control group was 0.1×10 6 LSL-mCherry 293 cells were cultured alone; 293+FMLV ENV group was 0.1×10 6 LSL-mCherry 293 cells + 0.1 × 10 6 293T (VLP-CRE) cells were co-cultured, and the envelope protein of 293T cells was Friend MLV Env YFP plasmid when transfected; the XC control group was 0.1×10 6 LSL-mCherry XC cells were cultured alone; XC+FMLV ENV group was 0.1×10 6 LSL-mCherry XC cells + 0.1×10 6 293T (VLP-CRE) cells were co-cultured, and the envelope protein when transfecting 293T cells was Friend MLV Env YFP plasmid.
[0163] The results, as shown in Figure 4, demonstrate that the specificity of VLP delivery via direct cell-cell contact can be regulated by the envelope protein. VLPs encapsulated with the envelope protein FMLV ENV could only be delivered to XC cells that possess the FMLV ENV membrane receptor, but not to LSL-mCherry 293 cells (the target cells) that lack this receptor.
[0164] Example 6 Effect of Capsid Protein pBS-CMV-gagpol (GAG WT) and Its Mutant Plasmids on VLP Budding Rate
[0165] In this example, donor delivery cells (293T cells) were individually transfected with different GAG plasmids, including wild-type GAG plasmid and four mutants, to examine the budding of VLPs packaged by the GAG plasmids alone.
[0166] 6.1 Experimental steps for transfecting 293T (VLP-CRE) cells (donor delivery cells) according to Example 2. The transfection plasmid was pBS-CMV-gagpol (GAG WT) or four different mutant GAGmu plasmids, namely pBS-CMV-gagpol S3R mutant (GAG S3R), pBS-CMV-gagpol NC60 (GAG NC60), pBS-CMV-gagpol NC16-23 (GAG NC16-23), and pBS-CMV-gagpol P12 (GAG P12).
[0167] 6.3 ELISA for detecting GAG p30 protein content in cells and VLPs
[0168] 1) After 48 hours of co-culture, the cell supernatant was collected and purified by ultracentrifugation or concentration;
[0169] 2) At the same time, 293T cells were collected and lysed with RIPA solution (coolaber, SL1010);
[0170] 3) Appropriately dilute the VLP and cell samples and assay the GAG p30 protein content in the VLPs and cells using a p30 ELISA kit (Cell Biolabs, VPK-156). Calculate the ratio of p30 protein in the VLP to the total p30 protein to characterize the budding success rate of the different mutants. Refer to the p30 ELISA kit instructions for the ELISA assay for p30 protein content.
[0171] 6.4 Experimental Results
[0172] The results are shown in Figure 5 , and the mutant GAG plasmid significantly reduced the budding rate of VLP.
[0173] Example 7 Differences in direct cell delivery of VLPs by capsid protein pBS-CMV-gagpol (GAG WT) and its mutants
[0174] In this example, 293T (VLP-CRE) cells capable of delivering VLPs containing CRE recombinase were prepared by referring to Example 2, except that different capsid proteins were used, namely, wild-type pBS-CMV-gagpol (GAG WT), its mutant pBS-CMV-gagpol S3R mutant (GAG S3R), pBS-CMV-gagpol NC60 (GAG NC60), pBS-CMV-gagpol NC16-23 (GAG NC16-23), and pBS-CMV-gagpol P12 (GAG P12). In addition, a separate group was set up in which no GAGPOL plasmid was added (no-GAG). All other conditions were exactly the same.
[0175] 7.1 Preparation of 293T (VLP-CRE) Donor Delivery Cells
[0176] Please refer to Example 2 for the specific steps.
[0177] 7.2 Direct cell delivery of VLPs
[0178] Six groups of 293T (VLP-CRE) donor cells were co-cultured with LSL-mCherry 293 target cells for 48 hours. The cells were then collected and flow cytometry analyzed to determine the proportion of gene recombination events in the target cells. The delivery method was similar to that of the direct delivery group in Example 3.
[0179] 7.3 Experimental Results
[0180] The results are shown in Figure 6. Compared with the blank control group and the no-GAG group, the receptor target cells in the GAG plasmid group clearly underwent gene recombination events, and the mutant GAG plasmid increased the gene recombination rate of the receptor target cells to varying degrees.
[0181] Example 8: Introducing CD19 CAR and its target antigen CD19 to enhance the targeting of donor-delivered cells
[0182] In this example, CD19 CAR-Jurkat T cells were constructed as donor delivery cells carrying CD19 CAR. At the same time, CD19 antigens were added to the cell membrane of the recipient target cells (LSL-mCherry 293 cells) constructed in Example 1 to construct CD19-LSL-mCherry 293 cells as the recipient target cells of this example. After electroporation, CD19 CAR-Jurkat T cells can produce virus-like particles loaded with the Cre recombinase gene. After treatment, CD19 CAR-Jurkat T cells are directly or indirectly contacted with the recipient target cells to deliver virus-like particles loaded with the Cre recombinase gene. Whether the delivery of CD19 CAR-Jurkat T virus-like particles depends on direct contact is confirmed by whether the recipient target cells express red fluorescent protein (mCherry).
[0183] 8.1 Construction of Donor Delivery Cells CD19 CAR-Jurkat T Cells
[0184] 1) Packaging CD19 CAR lentivirus;
[0185] 2) Using CD19 CAR lentivirus to infect Jurkat T cells, i.e., CD19 CAR-Jurkat T cells;
[0186] 3) The cells were cultured and frozen for subsequent experiments.
[0187] 8.2 Construction of receptor target cells CD19-LSL mCherry cells
[0188] 1) Packaging CD19 target antigen lentivirus
[0189] 2) Infecting the receptor target cells LSL-mCherry 293 cells constructed in Example 1 with CD19 target antigen lentivirus, and then overexpressing CD19 antigen on the cell surface;
[0190] 3) After the infected cells have grown to a sufficient number, harvest them, incubate with CD19 antibodies, and filter out CD19-positive cells using flow cytometry, identifying them as CD19-LSL-mCherry 293 cells. Continue culturing the cells and cryopreserving them for subsequent experiments.
[0191] 4) Use similar methods to construct other receptor target cells carrying CD19 antigen: CD19-LSL-mCherry XC cells, CD19-LSL-mCherry Jurkat T cells and other receptor target cells containing gene recombination reporter systems.
[0192] 8.3 Activated CD19 CAR-Jurkat T Cell Testing
[0193] Donor-delivered CD19 CAR-Jurkat T cells with good growth status were co-cultured with recipient target cells CD19-LSL-mCherry 293 at an effector-target ratio of 1:1 for 24 hours. The activated CD19 CAR-Jurkat T cells were labeled with CD69 antibody and detected by flow cytometry.
[0194] 8.4 Experimental Results
[0195] Flow cytometric analysis results showed (Figure 7) that after 24 hours of co-culture of the constructed CD19 CAR-Jurkat T cells with the receptor target cells CD19-LSL-mCherry 293, most of the CD19 CAR-Jurkat T cells were activated, while very few control Jurkat T cells were activated, indicating that CD19 CAR-Jurkat T cells can specifically recognize the receptor target cells CD19-LSL-mCherry 293 cells.
[0196] Example 9: Differences in the efficiency of direct or indirect delivery of VLPs by CD19 CAR-Jurkat T cells
[0197] 9.1 Electroporation to construct CD19 CAR-Jurkat T donor delivery cells containing virus-like particles
[0198] The CD19 CAR-Jurkat T cells constructed in Example 8 were counted, centrifuged and resuspended in opti-MEM to 5×10 7 / ml. Add 100 μl of CD19 CAR-Jurkat T cells to a mixture of pBS-CMV-gagpol (MLV gag and pol), pRP[Exp]-CMV+intron>{MMLVgag-3XNES-NLSCRE} (MMLVgag-3NES-Cre), and PMD 2.G (WTVSV-G) and prepare for electroporation. The electroporation parameters are listed in the table below. After electroporation, transfer the cells to 5 ml of 1640 medium and culture in a 37°C incubator for 48 hours to obtain cells capable of delivering VLPs containing the Cre recombinase.
[0199] 9.2 Direct Delivery Group: Recipient target cells (CD19-LSL-mCherry 293 cells) were directly contacted and co-cultured with electroporated donor delivery cells (CD19 CAR-Jurkat T cells) for 72 hours. The culture method was similar to that of the direct delivery group in Example 3.
[0200] 9.3 Indirect delivery group: Recipient target cells (CD19-LSL-mCherry 293 cells) and electroporated donor delivery cells (CD19 CAR-Jurkat T cells) were co-cultured in non-direct contact for 72 hours (VLPs were delivered by secretion). The culture method was similar to that of the indirect delivery non-concentration group in Example 3.
[0201] 9.4 After the culture, the CD19-LSL-mCherry 293 in the 24-well plate was digested with trypsin for flow cytometry detection.
[0202] 9.5 Experimental Results
[0203] The results are shown in Figure 8. The delivery efficiency of virus-like particles loaded with the CRE recombinase gene by CD19 CAR-Jurkat T cells through direct contact with CD19-LSL-mCherry 293 cells was significantly higher than that of VLPs delivered only through budding release from CD19 CAR-Jurkat T cells in the culture chamber (indirect delivery).
[0204] Example 10 CD19 CAR-Jurkat T cells deliver VLPs loaded with red fluorescent protein (RFP) to recipient target cells by direct contact
[0205] 10.1 CD19 CAR-Jurkat T cells were electroporated to package VLPs loaded with red fluorescent protein (RFP)
[0206] Electroporation was performed as described in Example 9, using pBS-CMV-gagpol (MLV gag and pol), MMLVgag-3NES-RFP, and PMD 2.G (WT VSV-G). Electroporated CD19 CAR-Jurkat T cells expressed red fluorescence.
[0207] 10.2 Microscopic imaging of the process of VLP transfer from donor delivery cells to recipient target cells
[0208] CD19 CAR-Jurkat T cells (red) electroporated and cultured for 48 hours were co-cultured with CD19-LSL-mCherry 293 cells (green) in a glass-bottomed culture dish for 16 hours. The Mica full-scene microscopy imaging and analysis platform was used to capture the process of donor delivery cells delivering virus-like particles containing red fluorescent protein (RFP) to recipient target cells, with images taken every 10 minutes.
[0209] 10.3 Experimental Results
[0210] As shown in Figure 9, CD19 CAR-Jurkat T cells (red) directly contacted CD19-LSL-mCherry 293 cells (green) and delivered virus-like particles containing red fluorescent protein (RFP) to CD19-LSL-mCherry 293 cells, while CD19-LSL-mCherry 293 cells (green) that were not in direct contact with CD19 CAR-Jurkat T cells (red) did not receive VLPs.
[0211] Example 11 CD19-CAR-Jurkat T-specific delivery of virus-like particles
[0212] In this example, CD19 CAR-Jurkat T cells containing CRE recombinase VLPs can be delivered and co-cultured with the CD19-LSL-mCherry 293 cells expressing the CD19 receptor target cells constructed in Example 8 and the LSL-mCherry 293 cells not expressing CD19 constructed in Example 2 to detect whether CD19 CAR-Jurkat T cells need to specifically recognize the CD19-expressing receptor target cells to deliver virus-like particles loaded with the Cre recombinase gene.
[0213] 11.1 Prepare CD19 CAR-Jurkat T cells capable of delivering CRE recombinase VLPs according to the method in 9.1
[0214] 11.2 Cell Co-culture
[0215] 150,000 electroporated CD19 CAR-Jurkat T cells were co-cultured with 5,000 CD19-LSL-mCherry 293 cells and 25,000 LSL-mCherry 293 cells in 24-well culture dishes in 0.5 mL of 1640 culture medium for 72 hours. After the culture, the CD19-LSL-mCherry 293 cells and LSL-mCherry 293 cells in the 24-well plates were digested with trypsin. The two groups of cells were distinguished by CD19 antibodies, and the difference in the delivery efficiency of CD19 CAR-Jurkat T cells to receptor target cells expressing CD19 and those not expressing CD19 was detected by flow cytometry.
[0216] 11.3 Comparison of Free VLP Delivery to Target Cells Expressing or Not Expressing CD19
[0217] The free VLPs produced by the purified donor delivery cells were collected using the method of indirect delivery of the concentrated VLP group in Example 3 and added to 24-well culture dishes containing 40,000 CD19-LSL-mCherry 293 cells or LSL-mCherry 293 cells and cultured for 72 hours. After the culture, the CD19-LSL-mCherry 293 cells or LSL-mCherry 293 cells in the 24-well plates were digested with trypsin, and the difference in delivery efficiency of CD19 CAR-Jurkat T cells to receptor target cells expressing CD19 and those not expressing CD19 was detected by flow cytometry.
[0218] 11.4 Experimental Results
[0219] When CD19-expressing and non-CD19-expressing target cells coexist, CD19 CAR-Jurkat T cells specifically recognize CD19-expressing target cells, resulting in a much higher delivery efficiency than non-CD19-expressing target cells (Figure 10A). Free VLPs, however, are unable to specifically recognize CD19-expressing or non-CD19-expressing target cells, resulting in no difference in delivery efficiency between the two types of target cells (Figure 10B).
[0220] Example 12 Effects of Different Effector-Target Ratios on CD19-CAR-Jurkat T Specific Delivery of Virus-Like Particles
[0221] At different ratios of donor delivered cells and recipient target cells, the differences between the CD19 CAR-Jurkat T cell and CD19-LSL-mCherry 293 recipient target cell groups and other delivery control groups were compared.
[0222] 12.1 Prepare CD19 CAR-Jurkat T cells that can deliver CRE recombinase VLP and control Jurkat T cells according to the method of 9.1
[0223] 12.2 Co-culture of Donor Delivery Cells and Recipient Target Cells
[0224] After electroporation, CD19 CAR-Jurkat T cells or Jurkat T cells were co-cultured in 12-well plates for 72 hours according to the combinations and ratios of donor delivery cells and recipient target cells as shown in the table below. After the culture period, the CD19-LSL-mCherry 293 cells or LSL-mCherry 293 cells in the 12-well plates were trypsinized, and the delivery efficiency of the donor delivery cells was quantitatively analyzed by flow cytometry to detect the proportion of mCherry and GFP double-positive cells after gene recombination in the recipient target cells.
[0225] 12.3 Experimental Results
[0226] Under different combinations of donor delivery cells and recipient target cells and different ratios of donor delivery cells to recipient target cells, CD19 CAR-Jurkat T cells achieved the best delivery efficiency to recipient target cells expressing CD19 (Figure 11). This indicates that the efficiency of CD19 CAR-Jurkat T cell delivery of VLPs depends on whether CD19 CAR-Jurkat T cells can specifically recognize recipient target cells.
[0227] Example 13 Effect of Capsid Protein pBS-CMV-gagpol and Its Mutant Plasmids on Specific Delivery of CD19-CAR-Jurkat
[0228] In this example, CD19 CAR-Jurkat T cells capable of delivering CRE recombinase VLPs were prepared by referring to the method of 9.1. Two GAG plasmid mutants were introduced during plasmid transfection, with three groups being wild-type pBS-CMV-gagpol (gagpol WT), pBS-CMV-gagpol S2D mutant (gagpol S2D), and pBS-CMV-gagpol NC60 (gagpol NC60). These mutations inhibit VLP budding, allowing CD19 CAR-Jurkat T cells to deliver VLPs only through direct contact, thereby improving the delivery capacity of CD19 CAR-Jurkat T cells.
[0229] 13.1 Referring to the method in 9.1, three groups of CD19 CAR-Jurkat T cells capable of delivering CRE recombinase VLPs and control Jurkat T cells were prepared using wild-type pBS-CMV-gagpol (gagpol WT), pBS-CMV-gagpol S2D mutant (gagpol S2D), and pBS-CMV-gagpol NC60 (gagpol NC60).
[0230] 13.2 CD19 CAR-Jurkat T cells deliver virus-like particles with different capsid proteins to CD19-LSL-mCherry 293 cells and LSL-mCherry 293 cells
[0231] The 13.1 electroporated CD19 CAR-Jurkat T cells were added to CD19-LSL-mCherry 293 cells expressing CD19 or CD19-LSL-mCherry 293 cells not expressing CD19 and co-cultured (as shown in the table below) in 24-well plates for 72 hours. After the culture, the CD19-LSL-mCherry 293 cells or LSL-mCherry 293 cells in the 24-well plates were digested with trypsin. The delivery efficiency of the donor delivery cells was quantitatively analyzed by detecting the proportion of mCherry+GFP+ cells after gene recombination of the recipient target cells by flow cytometry. The delivery specificity of different capsid protein VLPs was compared by comparing the delivery efficiency of CD19 CAR-Jurkat T cells to CD19-LSL-mCherry 293 cells with that of other control groups.
[0232] 13.3 CD19 CAR-Jurkat T cells and control Jurkat T cells deliver virus-like particles with different capsid proteins to CD19-LSL-mCherry 293 cells
[0233] CD19 CAR-Jurkat T cells and control Jurkat T cells after electroporation at 13.1 were added to CD19-LSL-mCherry 293 cells expressing CD19 (see the table below) and co-cultured in 12-well plates for 72 hours. After the culture, the CD19-LSL-mCherry 293 cells in the 24-well plates were digested with trypsin. The delivery efficiency of the donor delivery cells was quantitatively analyzed by detecting the proportion of mCherry+GFP+ cells after gene recombination of the recipient target cells by flow cytometry. The delivery specificity of different capsid protein VLPs was compared by comparing the delivery efficiency of CD19 CAR-Jurkat T cells with that of other control groups.
[0234] 13.4 Experimental Results
[0235] By comparing the ratio of CD19 CAR-Jurkat T cell delivery efficiency to target cells with different receptors (CD19-LSL-mCherry 293 / LSL-mCherry 293), it was found that virus-like particles with different capsid protein mutations can improve the specificity of CD19 CAR-Jurkat T cell delivery (Figure 12A), and the ΔNC60 mutation has a particularly significant improvement in delivery specificity (Figure 12A). By comparing the ratio of CD19 CAR-Jurkat T or Jurkat T cell delivery efficiency to target cells expressing the CD19 receptor (CD19 CAR-Jurkat T / CAR-Jurkat T), it was found that virus-like particles with different capsid protein mutations can also improve the specificity of CD19 CAR-Jurkat T cell delivery (Figure 12B). Therefore, these mutations inhibit VLP budding, so that CD19 CAR-Jurkat T cells can only deliver VLPs through direct contact, thereby improving the specificity of CD19 CAR-Jurkat T cell delivery.
Claims
1. A gene or gene therapy drug delivery system, the delivery system comprising a donor delivery cell containing virus-like particles, and the delivery system delivers the virus-like particles directly into a recipient target cell through the delivery cell.
2. The gene or gene therapy drug delivery system according to claim 1, characterized in that: The virus-like particles contain genes or gene therapy drugs.
3. The gene or gene therapy drug delivery system according to claim 2, characterized in that: The gene or gene therapy drug includes but is not limited to a DNA recombinase system, a ZFN (Zinc Finger Nuclease) system, a transposon system, a CRISPR-Cas 9 system, a TALEN system, a Prime-editing system and / or a gene epigenetic modification system.
4. The gene or gene therapy drug delivery system according to claim 3, characterized in that: The gene or gene therapy drug refers to a nucleic acid and / or its complex that can edit, insert or replace a gene to correct, compensate for defects or silence a disease-causing gene and normally express proteins, enzymes or polypeptides.
5. The gene or gene therapy drug delivery system according to claim 1, characterized in that: The delivery system relies on direct cell-cell direct interaction between donor delivery cells and recipient target cells to deliver virus-like particles, wherein the direct cell-cell contact includes in vitro cell co-culture with an inter-cell distance of 0-1 mm.
6. The gene or gene therapy drug delivery system according to claim 1, characterized in that: The virus-like particle does not include the genetic material of the virus, that is, it does not include the DNA or RNA genome of the virus itself, and the virus-like particle does not have the ability to replicate itself. The virus-like particle includes part or all of the virus's capsid protein, envelope protein and / or other structural proteins.
7. A delivery method that can be used to deliver genes or gene therapy drugs to recipient target cells, the method comprising directly contacting a donor delivery cell containing the gene or gene therapy drug with the recipient target cell, and the gene or gene therapy drug is directly transferred from the donor delivery cell to the recipient target cell.
8. The method for delivering a gene or a gene therapy drug to a receptor target cell as claimed in claim 7, characterized in that: The direct contact between the donor cell delivery cell and the recipient target cell can be carried out in vitro, in vivo or in an animal body.
9. Use of a gene or gene therapy drug delivery system in the preparation of a drug for improving physical condition or treating gene diseases, wherein the delivery system is the gene or gene therapy drug delivery system according to claims 1-6.
10. The use according to claim 9, characterized in that The improvement of physical condition includes improvement of body weight, improvement of aging, and improvement of physical fitness.
11. The use according to claim 9, characterized in that The genetic diseases include hereditary diseases and non-hereditary diseases, including but not limited to thalassemia, sickle cell anemia, hereditary retinal degeneration, specific lymphoma, familial hypercholesterolemia, cystic fibrosis, and spinal muscular atrophy (SMA).
Citation Information
Patent Citations
Cancer immunotherapy by delivering class II MHC antigens using a VLP-replicon
CN106232807A
HIV-1 virus-like particle and its prepn and use
CN1772892A
Vector to deliver and express foreign gene
WO1994008022A1
Method for delivering gene in cells
WO2020125576A1
